DaTaMabs Limited is a semi-virtual design house which invents and creates humanized antibody sequences for its collaborators. Using the skills and experience of its Scientific Founders, Tarran Jones and David Williams, DaTaMabs provides a royalty-free design service which is customised to meet your individual needs, expertise and budget.
DaTaMabs draws on 40 man-years of know-how and experience in the genetic manipulation and recombinant expression of therapeutic antibody candidates.
Crucially, following the design phase, DaTaMabs continues to provide support, enabling our clients efficiently to generate humanized antibody constructs, characterize their potency and select lead candidates.
We also have well-developed relationships with other service providers to provide all necessary capabilities, for collaborators who need them.
DaTaMabs provides you with access to the original, clinically-proven antibody humanization technology known as CDR grafting. This process reliably removes immunogenicity issues whilst retaining potency and specificity, as has been repeatedly demonstrated by over 200 clinical candidates and 18 regulatory- approved humanized antibodies worldwide.
The Founders of DaTaMabs have successfully humanized over 40 therapeutic antibody candidates in commercial collaborations with more than 20 biotech and pharma companies. These projects have led to the development of more than 10 clinical candidates, most of which are still in clinical trials.
There are now four humanized antibodies that were created by our design team which have achieved market approval. Two are already blockbuster drugs treating autoimmune diseases worldwide, whilst the latter two obtained regulatory approval this year. Significantly, these include a PD1-targeting antibody which is widely expected to be a “game-changer” in cancer therapy.